Get the Daily Brief
Latest Biotech News
New Arab Human Pangenome Assembled Using Long-Read Sequencing
A landmark study led by Mohammed Bin Rashid University assembled the first high-quality pangenome reference for Arab populations using PacBio’s HiFi long-read sequencing technology. Analyzing...
FDA Clears Sarepta Duchenne Therapy After Investigation
The FDA has resumed clearance for Sarepta Therapeutics' Elevidys gene therapy targeting ambulatory patients with Duchenne muscular dystrophy after a thorough safety review. This follows a...
Celcuity’s Breast Cancer Therapy Achieves Late-Stage Milestones
Celcuity reported positive phase III results for its breast cancer drug gedatolisib, significantly reducing progression risk in hormone receptor-positive, HER2-negative advanced tumors that were...
Adaptimmune Sells Cell Therapy Assets in Turnaround Effort
Cell therapy developer Adaptimmune announced the sale of its sarcoma therapy Tecelra and two late-stage assets to US WorldMeds for an upfront payment of $55 million, with potential $30 million in...
GSK Inks $12.5B Deal with Hengrui for COPD and More
GlaxoSmithKline has secured rights to 12 drug programs from Jiangsu Hengrui Pharmaceuticals, including the promising phase I COPD candidate HRS-9821, for $500 million upfront and up to $12 billion...
Breakthrough in Arab Human Pangenome Sequencing Posted
Mohammed Bin Rashid University of Medicine and Health Sciences and partners have published the first high-quality Arab human pangenome constructed using PacBio's HiFi long-read sequencing. The...
AI Augments Pharma R&D Decision-Making
Sanofi's CEO Paul Hudson revealed that the company integrates AI recommendations into its drug development decision process, using machine insights to guide progression through clinical phases....
MapLight Raises $373M to Advance CNS Disease Pipeline
MapLight Therapeutics secured a $372.5 million Series D funding round to fuel development of its pipeline candidates for CNS disorders, including schizophrenia and Alzheimer's disease. The...
Optogenetic Platform Enables Precise Molecular Control in Cells
KAIST researchers introduced RELISR, an optogenetic platform offering reversible, spatiotemporal regulation of protein and mRNA storage and release within living cells and animals. Utilizing...
Autophagy Mechanisms Reveal Therapy Pathways for Parkinson’s
University of Vienna scientists elucidated molecular mechanisms underpinning mitophagy initiation via transmembrane cargo receptors BNIP3 and NIX, detailing hierarchical flexibility in autophagy...
Ivermectin Mass Drug Administration Cuts Malaria Transmission
The BOHEMIA trial in Kenya demonstrated a 26% decrease in new malaria infections following mass administration of ivermectin to children aged 5–15. This cluster-randomized study confirms...
Sanofi CEO Endorses AI for Drug Development Decisions
Sanofi's CEO Paul Hudson revealed that the company utilizes artificial intelligence to assist in progressing drug candidates through development phases. The AI system dispassionately recommends...
Bavarian Nordic Acquisition Talks Trigger $3 Billion Bid
Vaccine manufacturer Bavarian Nordic has agreed to be acquired by a consortium led by private equity firms Nordic Capital and Permira in an all-cash deal valued at approximately $3 billion. The...
GSK Inks $500M Upfront Deal with Hengrui Pharma for COPD Pipeline
GlaxoSmithKline (GSK) has agreed to a licensing deal worth $500 million upfront with China’s Jiangsu Hengrui Pharmaceuticals, acquiring rights to an experimental COPD drug and options on 11 other...
Abivax Shares Surge Following Phase III Ulcerative Colitis Data
Abivax's oral ulcerative colitis drug obefazimod surpassed expectations in Phase III trials, prompting a Nasdaq offering that was oversubscribed fivefold and raised nearly $750 million. CEO Marc...
MapLight Raises $373 Million to Advance CNS Drug Pipeline
California biotech MapLight Therapeutics secured a $372.5 million Series D financing round, one of the largest private funding events in 2025. The capital will support development of CNS drug...
FDA and Safety Scrutiny Surround Sarepta’s Duchenne Gene Therapy
The FDA is investigating the death of an 8-year-old Brazilian boy treated with Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys, following previous patient fatalities linked...
Celcuity Breast Cancer Drug Surpasses Phase 3 Endpoints
Celcuity's experimental breast cancer combination therapy achieved its primary endpoints in a Phase 3 trial, setting the stage for an FDA filing anticipated in Q4. The trial results position...
Revvity Reports 4% Revenue Growth, Raises Annual Guidance Slightly
Revvity announced 4% year-over-year revenue growth in Q2 2025, driven by gains in diagnostics and life sciences segments. Revenues totaled $720.3 million, beating estimates, with diagnostics up 3%...
Promega and Longhorn Form Co-Marketing Pact for Testing Platforms
Promega and Longhorn Vaccines and Diagnostics signed a collaboration to co-market Longhorn's PrimeStore molecular transport media with Promega's Maxwell nucleic acid extraction platforms. This...